title: Functional characterization of a human receptor for neuropeptide FF and related peptides.
abstract: 1. Neuropeptides FF (NPFF) and AF (NPAF) are involved in pain modulation and opioid tolerance. These peptides were known to act through uncharacterized G protein-coupled receptors (GPCR). We describe here, using an aequorin-based assay as screening tool, that an orphan GPCR, previously designated HLWAR77, is a functional high affinity receptor for NPFF and related peptides. This receptor is further designated as NPFFR. 2. Binding experiments were performed with a new radioiodinated probe, [(125)I]-EYF, derived from the EFW-NPSF sequence of the rat NPFF precursor. Chinese hamster ovary (CHO) cell membranes expressing NPFFR bound [(125)I]-EYF with a K(d) of 0.06 nM. Various NPFF analogues and related peptides inhibited [(125)I]-EYF specific binding with the following rank order (K(i)): human NPAF (0.22 nM), SQA-NPFF (0.29 nM), NPFF (0.30 nM), 1DMe (0.31 nM), EYW-NPSF (0.32 nM), QFW-NPSF (0.35 nM), 3D (1.12 nM), Met-enk-RF-NH(2) (3.25 nM), FMRF-NH(2) (10.5 nM) and NPSF (12.1 nM). 3. The stimulatory activity of the same set of peptides was measured by a functional assay based on the co-expression of NPFFR, G(alpha 16) and apoaequorin. The rank order of potency was consistent with the results of the binding assay. 4. Membranes from NPFFR expressing CHO cells bound GTP gamma[(35)S] in the presence of SQA-NPFF. This functional response was prevented by pertussis toxin treatment, demonstrating the involvement of G(i) family members. 5. SQA-NPFF inhibited forskolin induced cyclic AMP accumulation in recombinant CHO cells in a dose dependent manner. This response was abolished as well by pertussis toxin pre-treatment. 6. RT -- PCR analysis of human tissues mRNA revealed that expression of NPFFR was mainly detected in placenta, thymus and at lower levels in pituitary gland, spleen and testis.
authors.affiliation: I.R.I.B.H.N., Université Libre de Bruxelles, Campus Erasme, 808 Route de Lennik, B-1070 Brussels, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Kotani
authors.forename: C
authors.initials: C
authors.lastname: Mollereau
authors.forename: M
authors.initials: M
authors.lastname: Detheux
authors.forename: E
authors.initials: E
authors.lastname: Le Poul
authors.forename: S
authors.initials: S
authors.lastname: Brézillon
authors.forename: J
authors.initials: J
authors.lastname: Vakili
authors.forename: H
authors.initials: H
authors.lastname: Mazarguil
authors.forename: G
authors.initials: G
authors.lastname: Vassart
authors.forename: J M
authors.initials: JM
authors.lastname: Zajac
authors.forename: M
authors.initials: M
authors.lastname: Parmentier
mesh_terms: D000331:Aequorin; D000818:Animals; D001667:Binding, Competitive; D016466:CHO Cells; D002118:Calcium / Q000378:metabolism; D003001:Cloning, Molecular; D005576:Colforsin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000378:metabolism; D020869:Gene Expression Profiling; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006801:Humans; D009842:Oligopeptides / Q000378:metabolism*; D037342:Pertussis Toxin; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D018013:Receptors, Neuropeptide / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D013379:Substrate Specificity; D013816:Thermodynamics; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
chemical_list: D009842:Oligopeptides; D012333:RNA, Messenger; D018013:Receptors, Neuropeptide; D010566:Virulence Factors, Bordetella; C083929:neuropeptide FF receptor; D005576:Colforsin; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D000331:Aequorin; C053651:phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide; C061209:A18Famide; D000242:Cyclic AMP; D037342:Pertussis Toxin; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D002118:Calcium